Nanoparticles: The future for platinum drugs or a research red herring?

Nanomedicine

Volumn 7, Issue 9, 2012, Pages 1285-1287

  Wheate, Nial J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

cancer; carbon nanotube; cisplatin; dendrimer; liposome; nanoparticle; oxaliplatin; passive targeting; polymer

Indexed keywords

NANOPARTICLE; PLATINUM DERIVATIVE;

DRUG RESEARCH; EDITORIAL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PLATINUM;

EID: 84866687113     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.108     Document Type: Editorial

References (19)

1. Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 39, 8113-8127 (2010).
2. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am. Fam. Physician 77, 311-319 (2008).
3. Stathopoulos GP, Boulikas T. Lipoplatin formulation review article. J. Drug Deliv. 2012, 581363 (2012).
4. Nowotnik DP, Cvitkovic E. ProLindac (AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic. Adv. Drug Deliv. Rev. 61, 1214-1219 (2009).
5. Dhar S, Liu Z, Thomale J, Dai H, Lippard SJ. Targeted single-walled carbon nanotube-mediated Pt(IV) prodrug delivery folate as a homing device. J. Am. Chem. Soc. 130, 11467-11476 (2008).
6. Ajima K, Maigne A, Yudasaka M, Iijima S. Optimum hole-opening condition for cisplatin incorporation in single-wall carbon nanohorns and its release. J. Phys. Chem. B. 110, 19097-19099 (2006).
7. Dhar S, Daniel WL, Giljohann DA, Mirkin CA, Lippard SJ. Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. J. Am. Chem. Soc. 131, 14652-14653 (2009).
8. Wan X, Zhang G, Liu S. pH-disintegrable polyelectrolyte multilayer-coated mesoporous silica nanoparticles exhibiting triggered co-release of cisplatin and model drug molecules. Macromol. Rapid Commun. 32, 1082-1089 (2011).
9. Wagstaff AJ, Brown SD, Holden MR et al. Cisplatin drug delivery using gold-coated iron oxide nanoparticles for enhanced tumour targeting with external magnetic fields. Inorg. Chim. Acta doi:10.1016/j.ica.2012.05.012 (2012) (Epub ahead of print).
10. Kirkpatrick GJ, Plumb JA, Sutcliffe OB, Flint DJ, Wheate NJ. Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin. J. Inorg. Biochem. 105, 1115-1122 (2011).
11. Pisani MJ, Wheate NJ, Keene FR, Aldrich-Wright JR, Collins JG. Anionic PAMAM dendrimers as drug delivery vehicles for transition metal-based anticancer drugs. J. Inorg. Biochem. 103, 373-380 (2009).
12. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63, 136-151 (2011).
13. Craig GE, Brown SD, Lamprou D, Graham D, Wheate NJ. Cisplatin tethered gold nanoparticles which exhibit enhanced reproducbility, drug loading and stability-a step closer to pharmaceutical approval? Inorg. Chem. 51, 3490-3497 (2012).
14. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl Acad. Sci. USA 105, 17356-17361 (2008).
15. Peng XH, Wang Y, Huang D et al. Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles. ACS Nano 5, 9480-9493 (2011).
16. Xie M, Xu Y, Liu J, Zhang T, Zhang H. Preparation and characterization of folate targeting magnetic nanomedicine loaded with cisplatin. J. Nanomater. 2012, 921034 (2012).
17. Feazell RP, Nakayama-Ratchford N, Dai H, Lippard SJ. Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J. Am. Chem. Soc. 129, 8438-8439 (2007).
18. Poland CA, Duffin R, Kinloch I et al. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat. Nanotech. 3, 423-428 (2008).
19. Mohamed BM, Verma NK, Davies AM et al. Citrullination of proteins: a common post-translational modification pathway induced by different nanoparticles in vitro and in vivo. Nanomedicine (Lond.) doi:10.2217/nnm.11.177 (2012) (Epub ahead of print).